Imnovid

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pomalidomide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma
Pomalidomide (Imnovid®; Pomalyst®), an analogue of thalidomide, is an immunomodulatory agent, with several mechanisms of action… (More)
  • table 1
Is this relevant?
Review
2017
Review
2017
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single…
The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2017
2017
PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
 
Is this relevant?
2016
2016
Pomalidomida (▼ Imnovid): riesgo de reactivación de la hepatitis B asociado a su uso
 
Is this relevant?
2016
2016
Pharmacoeconomic evaluation of pomalidomide (imnovid) use in treatment of patients with relapsed or refractory multiple myeloma who have received at least two lines of therapy comprising lenalidomide…
 
Is this relevant?
Review
2014
Review
2014
Pomalidomide: A Review of Its Use in Patients with Recurrent Multiple Myeloma
Oral pomalidomide (Imnovid® [EU]; Pomalyst® [USA]) in combination with dexamethasone (in the EU), is approved in several… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2013
2013
Produkt Imnovid
  • Wiener Klinisches Magazin
  • Wiener klinisches Magazin
  • 2013
Imnovid® ist ein neuer Wirkstoff aus der Klasse der IMiDs® (Immunmodulatoren). Mit einer Standarddosierung von 4 mg (orale Gabe… (More)
Is this relevant?